CatalYm Stock
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
Sign up today and learn more about CatalYm Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About CatalYm Stock
CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.
Funding History
November 2020 | $50.0M |
---|---|
November 2022 | $50.0M |
Management
Scientific Founder
Jörg Wischhusen
Board Member
Marianne Uteng
Managing Director and Chief Executive Officer (CEO)
Phil L’Huillier
Chief Scientific Officer (CSO)
Christine Schuberth Wagner
Board Member
Jonathan Tobin
Board Member
Andreas Wallnöfer
Board Member
Rogier Rooswinkel
CFO
Anne Burger
Board Member
Oskar Slotboom
Chief Medical Officer (CMO)
Eugen Leo
Chairman Of The Board
John Haurum
Board Member
Nathalie Weitemeyer
Board Member
Marc Lohrmann
Press
patents - Apr, 14 2024
Anti-gdf15 antibody and a dosage regimen for the treatment of cancerbusinesswire - Feb, 11 2024
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory ...reports - Jan, 27 2024
Endpoints News — Inside Genentech's AI ambitions to ...talent4boards - Jan, 13 2024
CatalYm adds Dr. Roy Baynes to its Board as Independent Director and announces additions to its Scientific Advisory Boardfinance - Dec, 21 2023
CatalYm Presents Data at SITC 2023 Annual Meeting Further ...